survivin siRNA

Survivin siRNA is a **synthetic small interfering RNA (siRNA) specifically designed to silence the expression of the survivin gene (BIRC5)**, which encodes an inhibitor of apoptosis protein highly overexpressed in a wide range of human tumors but not in most differentiated adult tissues. By binding to survivin mRNA, survivin siRNA mediates its degradation via the RNA interference pathway, leading to decreased survivin protein levels. This results in inhibited tumor cell proliferation, induction of apoptosis, cell cycle arrest at the G2/M phase, and enhanced sensitivity of tumor cells to chemotherapeutic agents such as cisplatin. Survivin siRNA has shown efficacy in a range of cancer cell lines in vitro and in xenograft models in vivo. Delivery systems for survivin siRNA include liposomal nanoparticles and chemical modifications (such as 2′-OMe) to improve stability and cellular uptake. No single pharmaceutical company owns a specific, marketed survivin siRNA drug, as this approach remains investigational and preclinical, with various academic and industrial groups developing proprietary candidates[1][2][3][5].

Other names

survivin-targeted siRNAsurvivin-specific siRNAsiRNA targeting survivin